At the time of writing, Teva- Pharmaceutical Industries Ltd. ADR [TEVA] stock is trading at $20.88, up 26.47%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The TEVA shares have gain 20.35% over the last week, with a monthly amount glided 27.08%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Teva- Pharmaceutical Industries Ltd. ADR [NYSE: TEVA] stock has seen the most recent analyst activity on July 10, 2024, when Argus upgraded its rating to a Buy but kept the price target unchanged to $20 for it. Previously, JP Morgan upgraded its rating to Neutral on March 08, 2024, and kept the price target unchanged to $14. On February 12, 2024, upgrade upgraded it’s rating to Overweight and revised its price target to $19 on the stock. Jefferies upgraded its rating to a Buy and increased its price target to $14 on January 23, 2024. Piper Sandler upgraded its rating to a Neutral and raised its price target to $12 on January 03, 2024. HSBC Securities started tracking with a Buy rating for this stock on December 18, 2023, and assigned it a price target of $13. In a note dated November 27, 2023, UBS upgraded an Buy rating on this stock and boosted its target price from $11 to $13.
For the past year, the stock price of Teva- Pharmaceutical Industries Ltd. ADR fluctuated between $10.00 and $19.31. Currently, Wall Street analysts expect the stock to reach $23.2 within the next 12 months. Teva- Pharmaceutical Industries Ltd. ADR [NYSE: TEVA] shares were valued at $20.88 at the most recent close of the market. An investor can expect a potential return of 11.11% based on the average TEVA price forecast.
Analyzing the TEVA fundamentals
According to Teva- Pharmaceutical Industries Ltd. ADR [NYSE:TEVA], the company’s sales were 16.81B for trailing twelve months, which represents an 13.40% jump. Gross Profit Margin for this corporation currently stands at 0.5% with Operating Profit Margin at 0.13%, Pretax Profit Margin comes in at -0.03%, and Net Profit Margin reading is -0.06%. To continue investigating profitability, this company’s Return on Assets is posted at -0.02, Equity is -0.15 and Total Capital is 0.08. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of3.13.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 19.59 points at the first support level, and at 18.30 for the second support level. However, for the 1st resistance point, the stock is sitting at 21.61, and for the 2nd resistance point, it is at 22.34.
Ratios To Look Out For
It is important to note that Teva- Pharmaceutical Industries Ltd. ADR [NYSE:TEVA] has a current ratio of 0.89. As well, the Quick Ratio is 0.61, while the Cash Ratio is 0.24. Considering the valuation of this stock, the price to sales ratio is 1.41, the price to book ratio is 3.90.
Transactions by insiders
Recent insider trading involved Fox Christine, EVP, Head of U.S. Commercial, that happened on Nov 20 ’24 when 19388.0 shares were sold. Officer, Fox Christine completed a deal on Nov 20 ’24 to buy 19388.0 shares. Meanwhile, Exec. VP, European Commercial Daniell Richard sold 98943.0 shares on Aug 12 ’24.
